ALYFTREK (Deutivacaftor; Tezacaftor; Vanzacaftor Calcium) Patent Expiration, LOE Window & CMS Spending

ALYFTREK (Deutivacaftor; Tezacaftor; Vanzacaftor Calcium) by Vertex Pharmaceuticals: FDA Orange Book core substance LOE 2040-08-13 (last listed 2043-01-10), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $28,404 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVertex Pharmaceuticals
FDA Application & PathwayN218730 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-08-13
Last Listed Patent or Exclusivity Date2043-01-10
Orange Book Patents (*PED Extensions)94 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($28,404 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.